Almirall SA (ALM.MC)
9.59EUR
19 Jun 2013
€-0.01 (-0.10%)
€9.60
€9.63
€9.63
€9.51
20,485
171,490
€10.82
€5.31
ALM.MC
About
Overall
| Beta: | 0.45 |
| Market Cap (Mil.): | €1,660.33 |
| Shares Outstanding (Mil.): | 172.95 |
| Dividend: | 0.15 |
| Yield (%): | 1.59 |
Financials
| ALM.MC | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.42 | 30.37 | 30.65 |
| EPS (TTM): | 0.45 | -- | -- |
| ROI: | 7.10 | 19.50 | 18.83 |
| ROE: | 8.58 | 20.27 | 19.74 |
Almirall, Forest to seek approval for inhaler drug in US, Europe
MADRID, May 2 - Spain's Almirall and Forest Laboratories said on Thursday that results of a second phase III clinical trial for a new inhaler were positive and they will seek regulatory approval to sell the drug by the end of the year.
REFILE-Almirall, Forest report positive results in inhaler trial
MADRID, April 16 - Spain's Almirall and Forest Laboratories said results of a first phase III clinical trial for Almirall's Genuair inhaler were positive and they would seek regulatory approval to sell the drug if further results proved positive.
Almirall, Forest report positive results in inhaler trial
MADRID - Spain's Almirall and Forest Laboratories said results of a first phase III clinical trial for Almirall's Genuair inhaler were positive and they would seek regulatory approval to sell the drug if further results proved positive.
GW, Almirall may pull cannabis drug in German price row
LONDON - GW Pharmaceuticals and Almirall may stop selling the cannabis drug Sativex in Germany after health authorities refused to agree a price that the companies view as acceptable.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Wright Reports
|
$460.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: GlobalData
|
$125.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
